CDH5 and neoplasm: Cisplatin–DNA adduct formation in vivo in VE-cadherin KD tumours versus parental controls was decreased twofold, 1 h following a single dose of cisplatin (i.p.), in size-matched tumours (Fig. 8, left panel); 8.4 versus 4.0% of nuclei stained positively for cisplatin adducts in H446 parental versus H446 VE-cadherin KD xenografts (P=0.0052; Fig. 8, right panel).